Data as of Q4 2025 (Dec 31, 2025)

GREAT POINT PARTNERS LLC

โ€ขCIK: 1281446โ€ขFiling: Q4 2025

**GREAT POINT PARTNERS LLC** manages $308M across a concentrated portfolio of 29 positions. The fund exhibits significant conviction in its top holdings, with APGE representing the largest allocation at $28.2M. Notable concentrations include AMLX ($21.1M), RJF ($20.0M), and IRON ($19.9M), suggesting a focus on specific, high-conviction sector plays. This structure indicates a tactical, bottom-up approach targeting outsized returns within its selected names.

Total AUM
$308.4M
QoQ Performance
+28.8%
Positions
29
Top 10 Concentration
62.0%
Latest Filing
Q4 2025

Top Holdings Allocation

APGE
AMLX
ZURA
IRON
RAPT
IMVT
SLNO
VOR
APGE9.2%
AMLX6.9%
ZURA6.5%
IRON6.4%
RAPT6.4%
IMVT6.2%
SLNO6.0%
VOR5.8%

๐Ÿ“ˆ Biggest Buys

IRON
DISC MEDICINE INC
NEW
6.4% of portfolio
RAPT
RAPT THERAPEUTICS INC
NEW
6.4% of portfolio
VOR
VOR BIOPHARMA INC
NEW
5.8% of portfolio
KALV
KALVISTA PHARMACEUTICALS INC
NEW
3.6% of portfolio
CTNM
CONTINEUM THERAPEUTICS INC
NEW
3.0% of portfolio

๐Ÿ“‰ Biggest Sells

NKTR
NEKTAR THERAPEUTICS
-29.8%
2.9% of portfolio
RZLT
REZOLUTE INC
-61.2%
0.7% of portfolio
โ€”
PHARVARIS N V
-46.6%
0.7% of portfolio
NGNE
NEUROGENE INC
-21.7%
2.3% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

ASND
ASCENDIS PHARMA A/S SPONSORED ADR
SOLD
$14.9M
ABVX
ABIVAX SA SPONSORED ADS
SOLD
$12.7M
CYTK
CYTOKINETICS INC COM NEW
SOLD
$8.2M
XENE
XENON PHARMACEUTICALS INC
SOLD
$8.0M
ISI
IONIS PHARMACEUTICALS INC
SOLD
$5.2M
+8 more exited positions

Changes from Q3 2025

NEW12 new positions
โ†‘6 increased
โ†“4 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023